GlassScriptPhysician profile
Terina D Williams
NPI 1528461845
$4,028.82
in general payments reported to CMS, 2019-2025
29 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.50 · 2022: $45.14 · 2023: $574 · 2024: $1,522 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,925 · Education: $36.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,925.46 |
| Education | $36.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $517.27 | 2023-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $399.62 | 2023-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $357.27 | 2023-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $334.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $308.77 | 2023-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $278.29 | 2024-2025 | Tarpeyo |
| Amgen INC. | $268.51 | 2023-2025 | Tavneos, Parsabiv, Krystexxa |
| Ardelyx, INC. | $248.38 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $240.40 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.86 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $106.27 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $104.95 | 2023-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.99 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $66.73 | 2024-2025 | Injectafer |
| Akebia Therapeutics INC | $64.31 | 2024-2025 | Vafseo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.91 | 2025 | |
| Lilly USA, LLC | $49.88 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $49.72 | 2024-2025 | Benlysta, Jesduvroq, Shingrix |
| Genzyme Corporation | $49.37 | 2023-2024 | |
| Scpharmaceuticals INC. | $38.36 | 2025 | |
| Opko Pharmaceuticals, LLC | $36.72 | 2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $24.18 | 2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $23.66 | 2024 | Lupkynis |
| Biogen, INC. | $23.15 | 2025 | Spinraza |
| Apellis Pharmaceuticals, INC. | $18.07 | 2025 | Empaveli |
| Travere Therapeutics, INC. | $17.44 | 2025 | |
| Vifor Pharma, INC. | $16.76 | 2023 | Veltassa |
| Ultragenyx Pharmaceutical INC. | $14.72 | 2023 | Crysvita |
| Daxor Corporation | $10.16 | 2023 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terina Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.